About remegen - REGMF
RemeGen Co., Ltd. is a biopharmaceutical company. It discovers, develops and commercializes biologics for the treatment of autoimmune, oncology, and ophthalmic diseases. The company was founded by Dr. Jianmin Fang and Wang Weidong on July 04, 2008 and is headquartered in Yantai, China.
REGMF At a Glance
RemeGen Co., Ltd.
No. 58, Beijing Middle Road
Yantai, Shandong 264006
| Phone | 86-535-6113513 | Revenue | 452.06M | |
| Industry | Pharmaceuticals: Major | Net Income | 98.72M | |
| Sector | Health Technology | 2025 Sales Growth | 89.567% | |
| Fiscal Year-end | 12 / 2026 | Employees | 3,048 | |
| View SEC Filings |
REGMF Valuation
| P/E Current | 60.964 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 51.505 |
| Price to Sales Ratio | 11.272 |
| Price to Book Ratio | 10.02 |
| Price to Cash Flow Ratio | 651.76 |
| Enterprise Value to EBITDA | 80.80 |
| Enterprise Value to Sales | 11.202 |
| Total Debt to Enterprise Value | 0.062 |
REGMF Efficiency
| Revenue/Employee | 148,312.696 |
| Income Per Employee | 32,388.735 |
| Receivables Turnover | 3.919 |
| Total Asset Turnover | 0.505 |
REGMF Liquidity
| Current Ratio | 1.429 |
| Quick Ratio | 1.191 |
| Cash Ratio | 0.869 |
REGMF Profitability
| Gross Margin | 80.573 |
| Operating Margin | 4.007 |
| Pretax Margin | 21.844 |
| Net Margin | 21.838 |
| Return on Assets | 11.027 |
| Return on Equity | 25.039 |
| Return on Total Capital | 11.873 |
| Return on Invested Capital | 18.526 |
REGMF Capital Structure
| Total Debt to Total Equity | 61.009 |
| Total Debt to Total Capital | 37.892 |
| Total Debt to Total Assets | 30.376 |
| Long-Term Debt to Equity | 20.835 |
| Long-Term Debt to Total Capital | 12.94 |